The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
XNW27011, a Claudin 18.2(CLDN18.2) targeted antibody-drug conjugate (ADC), in patients with CLDN18.2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJA): A phase 2 study.
 
Linlin Wang
No Relationships to Disclose
 
Tianshu Liu
No Relationships to Disclose
 
Zeng-Qing Guo
No Relationships to Disclose
 
Jieer Ying
No Relationships to Disclose
 
Meili Sun
No Relationships to Disclose
 
Qing Wen
No Relationships to Disclose
 
Zhenyang Liu
No Relationships to Disclose
 
Jingdong Zhang
No Relationships to Disclose
 
Ting Deng
No Relationships to Disclose
 
Jun Zhao
Employment - Evopoint Biosciences
Stock and Other Ownership Interests - Evopoint Biosciences
 
Lixin Wan
No Relationships to Disclose
 
Fangling Ning
No Relationships to Disclose
 
Feng Wang
No Relationships to Disclose
 
Jin Xia
No Relationships to Disclose
 
Dan Zhao
Employment - Evopoint Biosciences
 
Dongrun Zhu
Employment - Evopoint Biosciences
 
Hui Zhao
Employment - Evopoint Biosciences
Stock and Other Ownership Interests - Evopoint Biosciences Co., Ltd
 
Hongxia Zheng
Employment - Evopoint Biosciences
 
Jinming Yu
No Relationships to Disclose